The approach to target validation utilizes RNAi, CRISPR, and
ORF expression platforms to genetically perturb candidate target gene expression in relevant cancer cell lines, and then profile the resulting phenotypic changes with regard to their effect on various biochemical pathways.
Experimental disruption of the
ORF of an OR allele does not ablate its
expression, instead another OR allele is co-expressed in the same cell [45], [46].